Prognosis of APL cases stratified by WBC count at presentation and CD95 genotype
| Stratified at 3 × 109 L−1 . | CD95 −1377 status (*Events/Patients [%]) . | H.R. (95% CI) . | |
|---|---|---|---|
| GG . | GA + AA . | ||
| Overall Survival (5-y OS) | |||
| WBC count < 3 × 109 L−1 | 18/89 (84) | 6/25 (80) | 1.36 (0.50-3.70) |
| WBC count ≥ 3 × 109 L−1 | 28/97 (73) | 10/18 (44) | 3.54 (1.35-9.27) |
| Test for heterogeneity between subgroups: χ21 = 1.8; P = 0.18 | |||
| Relapse-free survival (5-y RFS) | |||
| WBC count < 3 × 109 L−1 | 16/86 (84) | 5/22 (82) | 1.31 (0.45-3.86) |
| WBC count ≥ 3 × 109 L−1 | 25/86 (73) | 8/13 (39) | 4.22 (1.39-12.77) |
| Test for heterogeneity between subgroups: χ21 = 2.2; P = 0.14 | |||
| Death from infection (5-y incidence) | |||
| WBC count < 3 × 109 L−1 | 6/89 (7) | 3/25 (12) | 2.18 (0.43-1.10) |
| WBC count ≥ 3 × 109 L−1 | 6/97 (7) | 5/18 (35) | 20.07 (3.37-119.5) |
| Test for heterogeneity between subgroups: χ21 = 3.3; P = 0.07 | |||
| Stratified at 10 × 109 L−1 | |||
| Overall Survival (5-y OS) | |||
| WBC count < 10 × 109 L−1 | 27/131 (17) | 9/34 (23) | 1.49 (0.65-3.43) |
| WBC count ≥ 10 × 109 L−1 | 19/55 (67) | 7/9 (22) | 7.08 (1.93-25.59) |
| Test for heterogeneity between subgroups: χ21 = 3.9; P = 0.05 | |||
| Disease-free survival (5-y RFS) | |||
| WBC count < 10 × 109 L−1 | 26/125 (82) | 10/30 (30) | 1.99 (0.85-4.69) |
| WBC count ≥ 10 × 109 L−1 | 15/47 (68) | 3/5 (40) | 2.96 (0.56-15.79) |
| Test for heterogeneity between subgroups: χ21 = 0.2; P = 0.7 | |||
| Death from infection (5-y incidence) | |||
| WBC count < 10 × 109 L−1 | 7/131 (5) | 4/34 (13) | 3.08 (0.68-13.88) |
| WBC count ≥ 10 × 109 L−1 | 5/55 (9) | 4/9 (44) | 7.23 (2.10-24.87) |
| Test for heterogeneity between subgroups: χ21 = 3.8; P = 0.05 | |||
| Stratified at 3 × 109 L−1 . | CD95 −1377 status (*Events/Patients [%]) . | H.R. (95% CI) . | |
|---|---|---|---|
| GG . | GA + AA . | ||
| Overall Survival (5-y OS) | |||
| WBC count < 3 × 109 L−1 | 18/89 (84) | 6/25 (80) | 1.36 (0.50-3.70) |
| WBC count ≥ 3 × 109 L−1 | 28/97 (73) | 10/18 (44) | 3.54 (1.35-9.27) |
| Test for heterogeneity between subgroups: χ21 = 1.8; P = 0.18 | |||
| Relapse-free survival (5-y RFS) | |||
| WBC count < 3 × 109 L−1 | 16/86 (84) | 5/22 (82) | 1.31 (0.45-3.86) |
| WBC count ≥ 3 × 109 L−1 | 25/86 (73) | 8/13 (39) | 4.22 (1.39-12.77) |
| Test for heterogeneity between subgroups: χ21 = 2.2; P = 0.14 | |||
| Death from infection (5-y incidence) | |||
| WBC count < 3 × 109 L−1 | 6/89 (7) | 3/25 (12) | 2.18 (0.43-1.10) |
| WBC count ≥ 3 × 109 L−1 | 6/97 (7) | 5/18 (35) | 20.07 (3.37-119.5) |
| Test for heterogeneity between subgroups: χ21 = 3.3; P = 0.07 | |||
| Stratified at 10 × 109 L−1 | |||
| Overall Survival (5-y OS) | |||
| WBC count < 10 × 109 L−1 | 27/131 (17) | 9/34 (23) | 1.49 (0.65-3.43) |
| WBC count ≥ 10 × 109 L−1 | 19/55 (67) | 7/9 (22) | 7.08 (1.93-25.59) |
| Test for heterogeneity between subgroups: χ21 = 3.9; P = 0.05 | |||
| Disease-free survival (5-y RFS) | |||
| WBC count < 10 × 109 L−1 | 26/125 (82) | 10/30 (30) | 1.99 (0.85-4.69) |
| WBC count ≥ 10 × 109 L−1 | 15/47 (68) | 3/5 (40) | 2.96 (0.56-15.79) |
| Test for heterogeneity between subgroups: χ21 = 0.2; P = 0.7 | |||
| Death from infection (5-y incidence) | |||
| WBC count < 10 × 109 L−1 | 7/131 (5) | 4/34 (13) | 3.08 (0.68-13.88) |
| WBC count ≥ 10 × 109 L−1 | 5/55 (9) | 4/9 (44) | 7.23 (2.10-24.87) |
| Test for heterogeneity between subgroups: χ21 = 3.8; P = 0.05 | |||
Events refers to failure to achieve deaths, relapses/deaths in CR or infection-related death, depending on the analysis.
H.R. indicates hazard ratio; 95% CI, 95% confidence interval; APL, acute promyelocytic leukemia; and WBC, white blood cell.